Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
3385-03-3
Molecular formula
C24H31FO6
Molecular weight
434.5 g/mol
Drug class
Synthetic glucocorticoidinhaled and intranasal corticosteroid anti-inflammatory agent
Mechanism of action
Activates intracellular glucocorticoid receptors and regulates transcription of inflammatory mediators, reducing airway and nasal mucosal inflammation, oedema and mucus production.
Indications / reported uses
Maintenance treatment of asthma with inhaled formulations; not for relief of acute bronchospasm
Treatment of nasal symptoms associated with seasonal or perennial allergic rhinitis with authorised intranasal formulations
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Flunisolide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Flunisolide Permitted Daily Exposure (PDE) report (the Flunisolide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Flunisolide Occupational Exposure Limit (OEL) report (the Flunisolide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.